The Effect of Prenatal Supplementation with Omega 3 Long Chain Polyunsaturated Fatty Acids (n-3 LCPUFA) on Childhood Allergic Disease at Six Years of Age

Karen P Best RGN, RM

This thesis is submitted for the degree of Doctor of Philosophy

Discipline of Paediatrics

Faculty of Health Sciences

University of Adelaide

June 2015
# Table of Contents

Table of Contents ........................................................................................................... ii

List of Tables ......................................................................................................................... ix

List of Figures ......................................................................................................................... xi

Abstract .................................................................................................................................. xii

Declaration ................................................................................................................................. xiv

Publications & presentations in support of this thesis .................................................... xvi

Acknowledgements .................................................................................................................. xviii

Abbreviations ............................................................................................................................ xx

1 Introduction & Background ................................................................................................. 1

Introduction ............................................................................................................................... 2

Allergic Disease ....................................................................................................................... 5

Sensitisation ............................................................................................................................... 6

The Atopic March ..................................................................................................................... 11

Atopic Eczema .......................................................................................................................... 13

Allergic Rhinitis/Rhino-conjunctivitis ............................................................................. 15

IgE-mediated Allergic Asthma .......................................................................................... 16

Long Chain Polyunsaturated Fatty Acids (LCPUFA) ................................................... 19

Current dietary intake of PUFA .................................................................................. 21

LCPUFA and Pregnancy .................................................................................................. 23

LCPUFA and Allergy ........................................................................................................ 24

Supporting evidence of prenatal n-3 LCPUFA .......................................................... 25
A Systematic Review of the Literature Omega-3 LCPUFA intake during pregnancy and allergic disease outcomes in the offspring: A systematic review and meta-analysis of observational studies and randomised controlled trials

Introduction ........................................................................................................................................... 27
Methods .................................................................................................................................................. 29
Search Strategy ..................................................................................................................................... 30
Results .................................................................................................................................................... 33
Participants ............................................................................................................................................ 34
Exposure/Intervention .......................................................................................................................... 50
Clinical Outcomes .................................................................................................................................. 51
Quality of Observational Studies ......................................................................................................... 52
Quality of RCTS ...................................................................................................................................... 54
Results of Observational Studies ......................................................................................................... 56
Eczema ................................................................................................................................................... 56
Rhino-conjunctivitis/Hayfever .............................................................................................................. 57
Asthma/wheeze ...................................................................................................................................... 57
Sensitisation .......................................................................................................................................... 58
Results of RCTs ....................................................................................................................................... 58
Eczema ................................................................................................................................................... 58
Rhino-conjunctivitis ............................................................................................................................... 60
Asthma .................................................................................................................................................. 60
Sensitisation .......................................................................................................................................... 61
Discussion .............................................................................................................................................. 64
Methods and study design of the six year allergy follow up of children at high hereditary risk of atopy born to mothers supplemented with n-3 LCPUFA during pregnancy

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>69</td>
</tr>
<tr>
<td>Aim</td>
<td>69</td>
</tr>
<tr>
<td>Hypothesis</td>
<td>69</td>
</tr>
<tr>
<td>Participants &amp; Methods</td>
<td>70</td>
</tr>
<tr>
<td>The Parent Trial</td>
<td>70</td>
</tr>
<tr>
<td>DOMInO Trial design and dietary treatments</td>
<td>70</td>
</tr>
<tr>
<td>DOMInO Trial randomisation &amp; Blinding</td>
<td>71</td>
</tr>
<tr>
<td>Enrolment to 1 &amp; 3 year allergy follow-up</td>
<td>72</td>
</tr>
<tr>
<td>6 year allergy follow participation</td>
<td>73</td>
</tr>
<tr>
<td>Primary Outcome</td>
<td>73</td>
</tr>
<tr>
<td>Secondary Outcomes</td>
<td>73</td>
</tr>
<tr>
<td>Trial Quality Outcomes</td>
<td>78</td>
</tr>
<tr>
<td>The Six Year Appointment</td>
<td>79</td>
</tr>
<tr>
<td>Study Invitation</td>
<td>79</td>
</tr>
<tr>
<td>Locating families</td>
<td>81</td>
</tr>
<tr>
<td>During the 6 year Appointment</td>
<td>82</td>
</tr>
<tr>
<td>After the 6 year appointment</td>
<td>83</td>
</tr>
<tr>
<td>Off-site Assessments</td>
<td>83</td>
</tr>
<tr>
<td>Assessment by Correspondence</td>
<td>85</td>
</tr>
<tr>
<td>Skin Prick Test</td>
<td>87</td>
</tr>
<tr>
<td>SPT Procedure</td>
<td>88</td>
</tr>
<tr>
<td>Safety</td>
<td>91</td>
</tr>
<tr>
<td>Allergen extracts</td>
<td>92</td>
</tr>
<tr>
<td>Assessment of Allergic Disease</td>
<td>97</td>
</tr>
<tr>
<td>Eczema</td>
<td>97</td>
</tr>
</tbody>
</table>
Results of the six year allergy follow up of children at high hereditary risk of atopy born to mothers supplemented with n-3 LCPUFA during pregnancy 

Introduction

Sample and participant flow

Non completers

Baseline Characteristics

Compliance with the intervention

SPT Completion

Assessment Location

Primary Outcome Analysis

Sensitivity analysis

Secondary Outcomes

Incidence of Eczema Symptoms

Severity of Eczema Symptoms
Wheeze ............................................................................................................. 134
Severity of wheeze and asthma ................................................................. 135
Categories of wheeze ................................................................................ 137
Rhinitis & Rhino-conjunctivitis ................................................................. 139
Severity of Rhinitis/Rhino-conjunctivitis ............................................... 140
Sensitisation .............................................................................................. 142
Trial Quality Outcomes ........................................................................... 144
Skin Prick Test ............................................................................................ 144
Child Health Questionnaire ....................................................................... 146
Safety Outcomes ......................................................................................... 148
Hospitalisation/Serious Adverse Events ................................................. 148
Quality Outcomes ....................................................................................... 149
Blinding ....................................................................................................... 149
Post Randomisation Characteristics ....................................................... 151
Socio-demographic Characteristics ......................................................... 151
Environmental Characteristics ............................................................... 153
DHA Intake .................................................................................................. 155
Dietary characteristics ............................................................................... 156
Anthropometrics & Activity ..................................................................... 159
Other Child Characteristics ....................................................................... 160
Discussion .................................................................................................... 161

5 Longitudinal analysis of childhood allergy outcomes of children at high hereditary risk of atopy born to mothers supplemented with n-3 LCPUFA during pregnancy .................................................................................................................. 168

Introduction ............................................................................................... 169
Aim ............................................................................................................... 169
Hypothesis ................................................................................................. 169
Methods ...................................................................................................... 170
Bibliography ......................................................................................................................... 204

Appendix 1: Participant Information Sheet ......................................................................... 217

Appendix 2: Participant Consent Form .............................................................................. 220

Appendix 3: Updated Contact Details Form ....................................................................... 222

Appendix 4: Appointment Confirmation Letter ................................................................. 223

Appendix 5: HREC Amendment Request to use Facebook ............................................... 224

Appendix 6: Skin Prick Test SOP ...................................................................................... 232

Appendix 7: Skin prick test results for parents ................................................................. 237

Appendix 8: Certificate for child ....................................................................................... 238

Appendix 9: GP letter with skin prick test results ............................................................... 239

Appendix 10: HREC Amendment Request – In home skin prick testing ...................... 240

Appendix 11: Case Report Form (CRF) ............................................................................ 247

Appendix 12: Child Health Questionnaire (CHQ) ............................................................ 269

Appendix 13: CRF completion Instructions ...................................................................... 274

Appendix 14: HREC Amendment Request – Verbal Consent ........................................ 288

Appendix 15: Statistical Analysis Plan .............................................................................. 294

Appendix 16: Guidelines for storage and monitoring of allergens ................................ 313

Appendix 17: ASCIA Abstract .......................................................................................... 316

Appendix 18: PSANZ Abstract .......................................................................................... 317
List of Tables

Table 1-1 Alternative diagnostic techniques to determine sensitisation .............. 8
Table 1-2 Global median n-3 LCPUFA intakes (mg/day) ................................. 21
Table 2-1 Prospective Observational Studies of maternal fish or n-3 LCPUFA intake during pregnancy and allergic disease in the offspring ........... 35
Table 2-2 Randomised controlled trials (RCTs) of maternal n-3 LCPUFA supplementation during pregnancy and allergic disease in the offspring ........................................................................................................... 46
Table 2-3 Summary of risk of bias assessment for included RCTs .............. 55
Table 3-1 Secondary outcome descriptions .................................. 74
Table 3-2 Additional secondary outcome descriptions ......................... 75
Table 3-3 List of allergen extracts used ........................................ 95
Table 3-4 Case report form (CRF) sections ........................................ 104
Table 3-5 CHQ-PF50 Health Concepts (Domains) ................................ 108
Table 4-1 Baseline demographic and clinical characteristics .................... 124
Table 4-2 Locations where 6 year assessments were completed ........... 127
Table 4-3 Severity of eczema symptoms at 6 years ................................ 133
Table 4-4 Severity of wheeze and parent reported asthma at 6 years ....... 136
Table 4-5 Categories of wheezing phenotypes with and without sensitisation 138
Table 4-6 Incidence & Severity of Rhinitis/Rhino-conjunctivitis .............. 141
Table 4-7 Sensitisation to individual allergen extracts at 6 years of age .... 143
Table 4-8 Six year follow up study quality outcomes – SPT Completion ..... 145
Table 4-9 Child Health Questionnaire ............................................. 147
Table 4-10 Six year follow up study quality outcomes - Blinding ............. 150
Table 4-11 Socio-economic status, carer education and occupation .......... 152
Table 4-12 Environment Characteristics at 6 years .............................. 154
Table 4-13  Child’s Current DHA Intake at 6 years .......................................................... 155
Table 4-14  Child Dietary Characteristics at 6 years ......................................................... 157
Table 4-15  Anthropometrics and Physical Activity ........................................................... 159
Table 4-16  Paracetamol and Ibuprofen use at 6 years ....................................................... 160
Table 5-1   Allergen extracts tested at 1, 3 & 6 years ......................................................... 173
Table 5-2   Allergic disease symptom questions at 1, 3 & 6 years ................................. 174
Table 5-3   Effect of n-3 LCPUFA supplementation on individual allergic disease symptoms at 1, 3 & 6 years ............................................................... 179
Table 5-4   Longitudinal analysis of treatment effect (n-3 LCPUFA vs control) on individual allergic disease symptoms across all years ................................. 180
Table 5-5   Risk of allergic disease with sensitisation between n-3 LCPUFA and control groups across 1-6 years ........................................................... 181
Table 5-6   Effect of n-3 LCPUFA supplementation on sensitisation at 1, 3 & 6 years .............................................................................................................. 185
Table 5-7   Overall association of egg sensitisation at 1 year to D. farinae sensitisation at 6 years ......................................................................................................... 187
Table 5-8   Association of egg sensitisation at 1 year to D. farinae sensitisation at 6 years in the n-3 LCPUFA group ................................................................. 188
Table 5-9   Association of egg sensitisation at 1 year to D. farinae sensitisation at 6 years in the control group ................................................................. 189
Table 5-10  Longitudinal analysis of treatment effect (n-3 LCPUFA vs control) on any sensitisation and sensitisation to individual allergen extracts across all years ......................................................................................................... 190
Table 5-11  Risk of sensitisation between n-3 LCPUFA and control groups across 1-6 years .............................................................................................................. 191
List of Figures

Figure 1-1 Immunoglobulin-E (IgE) and allergic reactions (12) ................................................................. 5
Figure 1-2 Sensitisation rates to food (egg and milk) and inhalant allergens (29) ........................................ 12
Figure 1-3 Prevalence of sensitisation to inhalant allergens and the incidence of poly-sensitisation vs mono-sensitisation (29) ........................................................................................................ 12
Figure 1-4 Classes of essential fatty acids and conversion pathways (59) .................................................... 20
Figure 2-1 Flow chart of literature search and eligibility of included studies .............................................. 33
Figure 2-2 Incidence of confirmed ‘atopic’ eczema (with sensitisation) at 12 months ........................... 59
Figure 2-3 Incidence of ‘any’ eczema (with or without sensitisation) 0-12months .................................... 59
Figure 2-4 Cumulative incidence of IgE mediated rhino-conjunctivitis 0-3 years ................................. 60
Figure 2-5 Incidence of ‘any positive skin prick test (SPT) 0-12 months .................................................. 61
Figure 2-6 Sensitisation to egg between 0-12 months ............................................................................. 63
Figure 2-7 Sensitisation to ‘any food’ at 12 months .................................................................................. 63
Figure 3-1 Skin Prick Test – Prick and lift action (148) ............................................................................ 88
Figure 3-2 Child (‘Cleo’) undergoing SPT procedure whilst watching a movie ........................................... 89
Figure 3-3 Diagram of SPT wheal measurement ....................................................................................... 90
Figure 3-4 Labelled Allergen Extracts for the 6 year assessment ............................................................. 92
Figure 4-1 Flow diagram of the nested allergy follow-up cohort of the DOMInO trial ..................... 121
Figure 4-2 Reasons for refusal to participate in the 6 year allergy follow-up ....................................... 122
Figure 4-3 Reasons for non-completion of skin prick test at the 6 year assessment ......................... 126
Figure 4-4 Incidence of IgE-mediated allergic disease symptoms with sensitisation defined as positive skin prick test ≥3mm at 6 years ........................................................................ 128
Figure 4-5 Primary outcome sensitivity analysis ..................................................................................... 130
Figure 4-6 Symptoms of eczema with and without sensitisation at 6 years and parent reported eczema ever ..................................................................................................................................... 131
Figure 4-7 Symptoms of wheeze with and without sensitisation at 6 years and parent reported asthma ever .............................................................................................................................. 134
Figure 4-8 Symptoms of rhinitis and rhino-conjunctivitis with and without sensitisation at 6 years and parent reported hayfever ever ........................................................................................................... 139
Figure 4-9 Sensitisation to individual allergen extracts at 6 years of age .............................................. 142
Figure 5-1 Sensitisation pattern 1-6 years ................................................................................................. 183
Abstract

There is general consensus that the remarkable increase in allergic disease over the last 30-40 years is due to environmental influences including lifestyle and diet. Due to a number of factors associated with an industrialised world, the gross imbalance of n-6 (omega 6) and n-3 (omega 3) polyunsaturated fatty acids (PUFA) in our diet is no longer concordant with our genetically determined biology. Data from clinical and animal studies suggest that dietary n-3 LCPUFA in early life may influence immune system development and immune cell function reducing inflammatory responses, however clinically beneficial effects are more conflicting.

I conducted a systematic review of the literature including observational studies of increased maternal dietary intake of n-3 PUFA and RCT evidence of prenatal n-3 LCPUFA supplementation on outcomes of allergic disease in the offspring. Whilst limitations of cohort studies are well recognised, the concordance between outcomes from both study designs is noteworthy and suggestive of benefits. The paucity of RCT evidence beyond early childhood however, makes it difficult to draw any strong conclusions regarding the effect prenatal n-3 LCPUFA supplementation.

The six year allergy follow up study was a double blind randomised controlled trial designed to investigate the effect of supplementation of women with a fetus at high risk of atopy with 900mg of n-3 LCPUFA or a blended vegetable oil (with no n-3 LCPUFA) on outcomes of allergic disease in the offspring. 668 families were invited to take part in an allergy assessment to determine the incidence of allergic disease symptoms (eczema, wheeze or allergic rhinitis) and sensitisation to determine food and aeroallergen sensitisation.
603 children (90.2% of eligible cohort) completed an allergy assessment at six years of age. Results show that n-3 LCPUFA supplementation in pregnancy does not reduce the overall incidence of IgE-mediated allergic disease at six years of age, 116/367 (31.48%) vs 106/336 (31.46%) control, aRR 1.04 (0.82, 1.33), p=0.73. However, secondary outcomes suggest that the intervention reduces the incidence of ‘sensitisation to house dust mite’ and parent reported ‘hayfever ever’, 49/367 (13.42%) vs 68/336 (20.30%), aRR 0.67 (0.44, 1.00), p=0.0495; 81/367 (22.05%) vs 98/336 (29.05%), aRR 0.77 (0.59, 1.01), p=0.055 respectively.

This cohort of children with high hereditary risk of allergy also completed assessment of allergic disease and sensitisation at 1 and 3 years of age. A longitudinal analysis was performed on 1, 3 and 6 year data indicating that there was not enough evidence to conclude that the relative risk of sensitisation (n-3 LCPUFA vs control) changed over time or was associated with any outcomes of allergic disease or sensitisation across all years.

There are plausible mechanisms by which increasing maternal dietary n-3 LCPUFA intake may modulate the fetal immune system and subsequent development of allergic disease in infants at risk of atopic disease. Although my results did not show a reduction in overall IgE associated disease at 6 years or impact on longitudinal outcomes (1, 3 and 6 years), they are consistent with previous studies and suggestive of benefits of prenatal n-3 LCPUFA supplementation on certain aspects of allergic disease, namely sensitisation. My results support the necessity to further investigate these outcomes and their relationship to the clinical expression of disease.
Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution. This work, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide.

The systematic review and meta-analysis in this thesis (Chapter 2) is currently with the editors of the American Journal of Clinical Nutrition. I am first author and main contributor to the paper, written under the guidance of my supervisors Professor Maria Makrides, A/Professor Mike Gold and Professor Declan Kennedy.

I confirm that I personally completed the majority of the six year allergy assessments. When it became necessary to enlist the help of research staff of the Child Nutrition Research Centre to complete some of the 6 year allergy assessments (due to the number of assessments required and multiple clinic locations) I coordinated all aspects of study management including training, delegation and quality assurance.
I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I acknowledge that copyright of published works contained within this thesis resides with the copyright holder(s) of those works. I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

____________________
Karen P Best
Publications & presentations in support of this thesis

Publications


Published Abstracts

Conference Presentations


Best K, Sullivan T, Gold M, Kennedy D, Martin J, Palmer D, Makrides M. Six Year Follow Up of Children at High Hereditary Risk of Allergy, Born To Mothers Supplemented With Docosahexaenoic Acid (DHA) in the DOMInO Trial. Perinatal Society of Australia & New Zealand, Melbourne Victoria, April 2015, (Oral presentation and abstract)
Acknowledgements

First and foremost I would like to thank the children who took part in this research project and their families. Without their unselfish commitment, this study would not have been possible.

Thank you to the staff of the Child Nutrition Research Centre for assisting with scheduling and re-scheduling of appointments, completion of assessments and general research support.

To the many South Australian metropolitan clinics and country Hospitals that accommodated me to complete the six year assessments, your support was invaluable in achieving follow-up of as many children as possible.

Thank you to my supervisors A/Professor Mike Gold and Professor Declan Kennedy for your guidance at steering committee meetings. A special thank you to Dr James Martin, not technically my supervisor but still attended every meeting with advice and clinical knowledge and thanks also to Tom Sullivan, the most amazing statistician and really nice person.
Thank you to the MS McLeod Foundation for provision of my Paediatric/Child Health Nursing PhD Scholarship.

A special thank you to my partner Jason and my children, Chloe, Liam and Lucy for your love, support and faith in my ability.

The final acknowledgement is for my principal supervisor, Professor Maria Makrides, thank you for your expert advice and guidance throughout this project. I have learned so much from you over the years and continue to do so. I am extremely grateful for the opportunities that you have provided me.

This research was supported by the National Health and Medical Research Council.
Abbreviations

AA: Arachidonic acid
ACTRN: Australian clinical trials registry number
ALA: Alpha-linolenic acid
ANZCO: Australian & New Zealand Coding of Occupations
aRR: adjusted relative risk
CNRC: Child Nutrition Research Centre
CI: Confidence interval
CHQ: Child Health Questionnaire
CNRC: Child Nutrition Research Centre
CRF: Case report form
*D. farinae*: *Dermatophagoides farinae*
*D. pteronyssinus*: *Dermatophagoides pteronyssinus*
DHQ: Diet history questionnaire
DHA: Docosahexaenoic acid
DMAC: Data Management & Analysis Centre
DOMInO: Docosahexaenoic Acid to optimise maternal and infant outcomes
EFA: Essential fatty acid
EMBASE: Excerpta Medica Database
EPA: Eicosapentaenoic Acid
FFQ: Food Frequency Questionnaire
FMC: Flinders Medical Centre
GCP: Good Clinical Practice
HDM: House dust mite
HLA: Human-leucocyte antigen
HREC: Human Research Ethics Committee
IgE: Immunoglobulin-E

ITT: Intention to treat

LA: Linoleic Acid

n: number of participants

NHMRC: National Health and Medical Research Council

PUFA: Poly unsaturated fatty acid

RCT: Randomised controlled trial

RR: Relative risk

SEIFA: Socio-Economic Indexes for Areas

SCORAD: standardised scoring system for atopic dermatitis

SMS: Short message service

SOP: Standard operating procedure

SPT: Skin prick test

WCH: Women’s & Children’s Hospital

WCHN: Women’s & Children’s Health Network